☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
App
Advertisement
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Mirum
Mirum Submits Application to the EMA for Marketing Authorization of Livmarli for Progressive Familial Intrahepatic Cholestasis
April 6, 2023
Mirum’s Livmarli (maralixibat) Receives the Label Expansion Approval from the US FDA for Alagille Syndrome in Infants Aged ≥3 Mont...
March 15, 2023
Mirum Reports sNDA Submission to the US FDA for Livmarli (maralixibat) to Treat Cholestatic Pruritus in Progressive Familial Intra...
February 15, 2023
Mirum’s Livmarli (maralixibat) Receives EMA’s CHMP Positive Opinion for Cholestatic Pruritus in Patients with Alagille Syndrome
October 17, 2022
PharmaShots Weekly Snapshots (November 15 - 19, 2021)
November 19, 2021
PharmaShots Weekly Snapshots (November 15 - 19, 2021)
November 19, 2021
Load more...
Back to Home